Modified arginine deiminase

Details Modified arginine deiminase Modified arginine deiminase

2000-11-28

2004-05-18

Caputa, Anthony C. (Department: 1642)

Chemistry: molecular biology and microbiology

Carrier-bound or immobilized enzyme or microbial cell;...

Enzyme or microbial cell is immobilized on or in an organic...

C435S191000, C435S180000, C435S188000

Reexamination Certificate

active

06737259

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to arginine deiminase modified with polyethylene glycol, to methods for treating cancer, and to methods for treating and/or inhibiting metastasis.
BACKGROUND OF THE INVENTION
Malignant melanoma (stage 3) and hepatoma are fatal diseases which kill most patients within one year of diagnosis. In the United States, approximately 16,000 people die from these diseases annually. The incidence of melanoma is rapidly increasing in the United States and is even higher in other countries, such as Australia. The incidence of hepatoma, in parts of the world where hepatitis is endemic, is even greater. For example, hepatoma is one of the leading forms of cancer in Japan and Taiwan. Effective treatments for these diseases are urgently needed.
Selective deprivation of essential amino acids has been used to treat some forms of cancer. The best known example is the use of L-asparaginase to lower levels of asparagine as a treatment for acute lymphoblastic leukemia. The L-asparaginase most frequently used is isolated from
E. coli
. However, clinical use of this enzyme is compromised by its inherent antigenicity and short circulating half-life, as described by Y. K. Park, et al,
Anticancer Res
., 1:373-376 (1981). Covalent modification of
E. coli
L-asparaginase with polyethylene glycol reduces its antigenicity and prolongs its circulating half-life, as described, for example, by Park,
Anticancer Res., supra
; Y. Kamisaki et al,
J. Pharmacol. Exp. Ther
., 216:410-414 (1981); and Y. Kamisaki et al,
Gann
., 73:47-474 (1982). Although there has been a great deal of effort to identify other essential amino acid degrading enzymes for the treatment of cancer, none have been approved, primarily because deprivation of essential amino acids, by definition, results in numerous, and severe, side effects.
It has been reported that enzymes which degrade non-essential amino acids, such as arginine, may be an effective means of controlling some forms of cancer. For example, arginine deiminase (ADI) isolated from
Pseudomonas pudita
was described by J. B. Jones, “The Effect of Arginine Deiminase on Murine Leukemic Lymphoblasts,” Ph.D. Dissertation, The University of Oklahoma, pages 1-165 (1981). Although effective in killing tumor cells in vitro, ADI isolated from
P. pudita
failed to exhibit efficacy in vivo because it had little enzyme activity at a neutral pH and was rapidly cleared from the circulation of experimental animals. Arginine deiminase derived from
Mycoplasma arginini
is described, for example, by Takaku et al,
Int. J Cancer
, 51:244-249 (1992), and U.S. Pat. No. 5,474,928, the disclosures of which are hereby incorporated by reference herein in their entirety. However, a problem associated with the therapeutic use of such a heterologous protein is its antigenicity. The chemical modification of arginine deiminase from
Mycoplasma arginini
, via a cyanuric chloride linking group, with polyethylene glycol was described by Takaku et al., Jpn.
J Cancer Res
., 84:1195-1200 (1993). However, the modified protein was toxic when metabolized due to the release of cyanide from the cyanuric chloride linking group.
There is a need for compositions which degrade non-essential amino acids and which do not have the problems associated with the prior art. The present invention is directed to these, as well as other, important ends.
SUMMARY OF THE INVENTION
The present invention is directed to arginine deiminase modified with polyethylene glycol. In a preferred embodiment, the arginine deiminase is modified with polyethylene glycol, having a total weight average molecular weight of about 1,000 to about 50,000, directly or through a biocompatible linking group.
Another embodiment of the invention is directed to methods of treating cancer, including, for example, sarcomas, hepatomas and melanomas. The invention is also directed to methods of treating and/or inhibiting the metastasis of tumor cells.


REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4609546 (1986-09-01), Hiratani
patent: 5372942 (1994-12-01), McGarrity et al.
patent: 5447722 (1995-09-01), Lang et al.
patent: 5468478 (1995-11-01), Saifer et al.
patent: 5474928 (1995-12-01), Takaku et al.
patent: 5804183 (1998-09-01), Filpula et al.
patent: 5916793 (1999-06-01), Filpula et al.
patent: 6132713 (2000-10-01), Fiipula et al.
patent: 0230777 (1987-08-01), None
patent: 0 372 752 (1990-06-01), None
patent: 0 414 007 (1991-02-01), None
patent: 0 897 011 (1999-02-01), None
patent: 53490 (1990-02-01), None
patent: 4-121187 (1992-04-01), None
patent: 3 209 338 (2001-09-01), None
patent: WO 94/05332 (1994-03-01), None
patent: WO 96/34015 (1996-10-01), None
patent: 98/33519 (1998-08-01), None
patent: 98/51784 (1998-11-01), None
Takaku et al (1993, Jpn. J. Cancer Res., vol. 84, pp. 1195-200).*
Poyart et al (2002, International Journal of Systematic and Evolutionary Microbiology, vol. 52, pp. 1247-1255).*
Tettelin et al (Jul. 20, 2001, Science, vol. 293, pp. 498-506).*
Degnan, et al, 1998, Infection and Immunity, 66(7):3050-58.*
Fraser, C. et al., “Borrelia burgdorferi(section 69 of 70) of the complete genome”, Dec. 16, 1997, Database Accession No. AE001183, XP 002211866.
Knodler, Leigh A. et al., “Cloning and Expression of a Prokaryotic Enzyme, Arginine Deiminase., from a Primitive EukaryoteGiardia intestinalis”, Journal of Biological Chemistry,Feb. 20, 1998, 273(8), 4470-4477, XP-002211868.
Abuchowski, A., et al., “Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase,”J. Biol. Chem.,1977, 252(11), 3582-3586.
Abuchowski, A., et al., “Treatment of L5178Y tumor-bearing BDF mice with a nonimmunogenicL-asparaginase,”Cancer Terat. Rep.,1979, 63(6), 1127-1132.
Gill, P., et al., “Inhibition of cell division in L5178Y cells by arginine-degrading mycoplasmas: the frole of arginine deiminase,”Can. J. Microbiol.,1970, 16, 415-419.
Habeeb, A.F.S.A., “Determination of free amino groups in proteins by trinitrobenzenesulfonic acid,”Analyt. Biochem.,1966, 14, 328-336.
Hershfield, M.S., et al., “Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase,”New Engl. J. Medicine,1987, 316(10), 589-596.
Jaffe, N., et al., “Favorable remission induction rate with twice weekly doses ofL-asparaginase,”Cancer Res.,1973, 33(1), 1-4.
Jones, J.B., “The effect of arginine deiminase on murine leukemic lymphoblasts,”Ph.D. Dissertation, The University of Oklahoma,1981, 1-165.
Kamisaki, et al., “Increased antitumor activity ofescherichia coliL-asparaginase by modification with monomethoxypolyethylene glycol,”Gann,1982, 73, 470-474.
Kamisaki, et al., “Reduction in immunogenicity and clearance frate ofescherichia coliL-asparaginase by modification with monomethoxypolyethylene glycol,”J. Pharmacol. Exp. Ther.,1981, 216(2), 410-414.
Kidd, J.G., “Asparaginase and Cancer—Yesterday and Today,”Cancer Res.,1970, 33, 1-14.
Kondo, K., et al., “Cloning and sequence analysis of the arginine deiminase gene from mycoplasma arginini,”Mol. Gen. Genet.,1990, 221, 81-86.
Misawa, S., et al., “High-level expression of mycoplasma arginine deiminase inescherichia coliand is efficient renaturation as an anti-tumor enzyme,”J. Biotechnology,1994, 36, 145-155.
Miyazaki, K., et al., “Potent growth inhibition of human tumor cells in culture by arginine deiminase purified from a culture medium of a mycoplasma-infected cell line,”Cancer Res.,1990, 50, 4522-4527.
Monfardini, C., et al., “A branched monomethoxypoly(ethylene glycol) for protein modification,”Bioconj. Chem.,1995, 6, 62-69.
Naio, M., et al., “Alteration of the substrate specificity of asperfillus oryzae &bgr;-galactosidase by modification with polyethylene glycol,”J. Appl. Biochem.,1984, 6, 91-102.
Oginsky, “[92] Isolation and determination of arginine and citrulline,”Meth. Enzymol.,1957, 3, 639-642.
Ohno, T., et al., “Cloning and nucleotide sequence of the gene encoding arginine deiminase of mycoplasma arginini,”Infect. Immun.,1990, 58, 3788-3795.
Park, Y.K., et al., “Pharmaco

Affiliated with

Also associated with

Rating

Modified arginine deiminase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified arginine deiminase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified arginine deiminase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3191381